ArticleDiscover oncology2025
A nomogram to predict cancer-specific survival of ocular melanoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a nomogram that accurately predicts cancer-specific survival (CSS) in patients with ocular melanoma (OM).
methodsPatient data for individuals diagnosed with OM between 2004 and 2015 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The patients were then randomly divided into a training group and a validation group. Multivariate Cox proportional hazards regression analysis was utilized to identify significant variables. Subsequently, an independent variable-based nomogram was developed. Finally, multiple methods were used to verify and evaluate the performance of the nomogram.
resultsA total of 5,053 eligible patients diagnosed with OM were randomly divided into a training group (n = 3,537, 70%) and a validation group (n = 1,516, 30%). Age, race, primary site, histological type, American Joint Committee on Cancer (AJCC) stage, SEER stage, surgery, radiotherapy and chemotherapy were identified as independent prognostic factors for predicting the CSS of OM. These factors were incorporated into the development of a nomogram. Compared with AJCC, the nomogram is better than AJCC in concordance index (C-index), receiver operating characteristic (ROC) curve, net reclassification index (NRI), integrated discrimination improvement index (IDI), calibration curve and decision curve analysis (DCA).
conclusionWe developed a nomogram that can be used to predict the 3, 5 and 8 years cancer-specific survival (CSS) rates for patients diagnosed with OM. The nomogram offers a more precise and personalized approach for predicting patient survival outcomes while assisting ophthalmologists in devising improved clinical management strategies and treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.